Skip to main content
For laboratory research use only. Not for human or veterinary use.
Free UPS Ground on 3+ vials · same business day by 2 PM ET
Bench Grade Peptides

Selank

Synthetic tuftsin analog studied in anxiolytic and immunomodulatory research literature.

Selank is supplied by Bench Grade Peptides as a lyophilized powder in a sealed, lot-numbered vial, for laboratory research use only — not for human or veterinary use.

Its published Certificate of Analysis (lot 00011/0011, analyzed September 3, 2026) is from AV Analytics, a third-party laboratory, and reports 99.76% purity by HPLC; every published lot is listed on the product's COA page. Vials ship at ambient temperature in protective packaging from Florida (Bench Grade Peptides LLC is registered in Dover, Delaware), with storage notes on the lot's certificate.

Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro (CAS 129954-34-3, C33H57N11O9, 751.88 g/mol). It extends tuftsin, the naturally occurring tetrapeptide Thr-Lys-Pro-Arg, with a Pro-Gly-Pro tail, a modification designed to slow enzymatic breakdown in research preparations. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.

Most of the published record on Selank comes from rodent behavioural models and from gene-expression studies, much of it from Russian laboratories. Investigators have examined its effect on the expression of signalling-related genes, its interaction with enzymes that degrade enkephalins, and immunological readouts inherited from the tuftsin literature.

Selank is often studied alongside Semax, another short peptide from the same institute, and the catalogue carries a combined Selank + Semax material for that reason. Published lot certificates are listed on the COA page. Selank is supplied as laboratory research material only.

Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it has not been evaluated or approved by the FDA and is not for human or veterinary use, and nothing here is a protocol or a recommendation.

Published research

  • Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
    Medvedev VE, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2007.PubMed →

Further reading in the lab library

Researchers also ordered

Browse the catalog